Open Terminal →

Analyses / JNJ

JNJ Johnson & Johnson As of Nov 19, 2026
$272.70

Defensive mega-cap pharma trading near the upper half of its 52-week range, with premium trailing valuation and mixed growth signals.

Setup: Quality defensive, range-bound Confidence: medium Horizon: 1-3 months Risk: medium Category: Large Cap
🔒 Trade Plan — entry · target · stop
Entry Zone
$•••–•••
Target
$•••
Stop Loss
$•••
Risk / Reward
•.• : 1
Unlock the exact levels — free →

A free account reveals JNJ's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Forward P/E of 24.7x (price vs next-year earnings) is well below the trailing 41.1x, implying expected earnings recovery. EPS growth of 17.9% outpaces 5.6% revenue growth. Operating margin 34.6% and net margin 28.5% are strong. Beta of 0.17 and a 3.1% dividend yield suggest low sensitivity to broad market swings. If the stock holds above the 272.6 day low, a retest of the 52-week high near 290.2 is possible.

▼ Bear Case

Trailing P/E of 41.1x, P/B of 6.1x and P/S of 7.0x leave little valuation cushion if growth slows. Revenue growth of 5.6% (5-year average 2.7%) is modest for the multiple. Insiders sold 1.54M shares versus 1.43M bought across 266 transactions. Current ratio of 1.03 and quick ratio of 0.69 are thin. Shares fell 2.2% on the day and trade about 6% below the 52-week high.

Valuation

FULL PREMIUM — score 35/100

Trailing multiples are rich, while forward P/E and margins are more supportive.

Technical Levels

Support · $272.58 (Day low) · $275.55 (Day open)

Resistance · $278.70 (Prior close) · $290.25 (52-week high)

RSI: Not available in payload

Financial Health

Score 60/100. Profitability is strong, but liquidity ratios are thin and leverage data is missing from the payload.

Catalysts

Revenue growth acceleration above the 5.6% trailing rateNext quarterly report (date not in payload)high
Reclaim of the 290.25 52-week highWithin 1 to 3 months if momentum resumesmedium
Continued insider net sellingOngoing Form 4 filingslow

Risk Flags

RSI, PEG, ROE, ROIC, debt-to-equity and free cash flow per share are missing from the payload; related scores are limited.
Fundamentals, balance sheet, cash flow and sentiment blocks are null in the payload.
Trailing P/E of 41.1x sits well above the forward P/E of 24.7x, so the valuation read depends on earnings delivery.
News timestamps are unverified provider values; confirm dates at the source before relying on them.

See JNJ's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock JNJ free →

Recent News

More Analyses

JNJ FAQ

Is JNJ a buy right now?

Johnson & Johnson's current read is a Quality defensive, range-bound setup with medium confidence over a 1-3 months horizon. Valuation: FULL PREMIUM. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is JNJ overvalued?

FULL PREMIUM (valuation score 35/100). Trailing multiples are rich, while forward P/E and margins are more supportive.

What are the risks of buying JNJ?

Trailing P/E of 41.1x, P/B of 6.1x and P/S of 7.0x leave little valuation cushion if growth slows. Revenue growth of 5.6% (5-year average 2.7%) is modest for the multiple. Insiders sold 1.54M shares versus 1.43M bought across 266 transactions. Current ratio of 1.03 and quick ratio of 0.69 are thin. Shares fell 2.2% on the day and trade about 6% below the 52-week high.